Navigation Links
Clinical sequencing technology identifies new targets in diverse cancers
Date:6/7/2013

PHILADELPHIA Novel abnormalities in the FGFR gene, called FGFR fusions, were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

FGFR genes are receptors that bind to members of the fibroblast growth factor family of proteins and play a role in key biological processes of a human cell. Because of a chromosomal abnormality, this gene sometimes fuses with another gene and forms a hybrid, or a gene fusion, resulting in a gene product with an entirely different function, causing cancers.

"We found targetable FGFR gene fusions across a diverse array of cancer types. Although rare for any individual cancer type, if found in an individual patient, these fusions are likely a major driver of that patient's cancer," said Arul M. Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology at the University of Michigan in Ann Arbor. "We were surprised to find so many different FGFR fusions in so many different cancers.

"This study demonstrates the benefit of broad-based sequencing efforts in personalized oncology. It has the potential to identify novel, rare mutations that are 'actionable' therapeutic targets," Chinnaiyan added. "Such advances in sequencing technology facilitate rational precision therapies for individuals with late-stage cancer."

The Michigan Oncology Sequencing Program (MI-ONCOSEQ) facilitates integrative sequencing analysis of tumors from patients with advanced cancers. More than 100 patients have been enrolled since 2011. Through the project, researchers analyze the mutational landscape of each patient's tumor and suggest clinical trials or approved drugs that might be appropriate for that patient, according to Chinnaiyan.

He and his colleagues identified novel fusions of the gene FGFR2 in the tumors of four patients recruited to MI-ONCOSEQ. Of these four patients, two had metastatic tumors of the bile duct; the third had metastatic breast cancer and the fourth had metastatic prostate cancer.

To further analyze whether FGFR fusions are present across different types of cancers, the researchers extended their assessment and analyzed data generated from an internal cohort of 322 patients, as well as from a large cohort of 2,053 patients recruited to The Cancer Genome Atlas. They identified several distinct FGFR fusions in nine different types of cancers, including bladder cancer, brain cancer and lung cancer.

Chinnaiyan and colleagues then conducted studies using cancer cells and found that the different FGFR fusion proteins all seemed to drive cancer cell proliferation by activating FGFR signaling. The researchers were able to inhibit proliferation of the cells in vitro using the FGFR inhibitors PD173074 and pazopanib. In addition, they injected mice with human cancer cells and found that the tumors grown in mice could be inhibited with PD173074.

One of the four patients whose metastatic bile duct tumor failed to respond to conventional chemotherapy was recruited to an FGFR inhibitor trial, and he is currently undergoing treatment, according to Chinnaiyan.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces Prescription hCG Diet Plans Now With Unlimited Clinical Support For All Patients
2. African Mango Plus is Clinically Proven Effective Formula to Increase the Energy Level of the Body
3. AAOS releases revised clinical practice guideline for osteoarthritis of the knee
4. HealthCarePoint Pledges More Than $10 Million in Software and Technology Services to Help Support ACRES Global Network for Clinical Research
5. NIH to fund clinical research network on antibacterial resistance
6. New Hepatitis C Clinical Trial Now Enrolling at Avail Clinical Research near Orlando, Florida; Accepting M/F Patients with Hep C Age 18-65
7. Low Back Pain Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with Chronic Low Back Pain Age 18-80
8. Back2Basics Outdoor Adventures Names John Valvo as New Clinical Director
9. ATS publishes clinical practice guidelines on sleep apnea and driving
10. Medstreaming Appoints Vascular Health Care Veteran Keith Fujioka as VP of Clinical Services
11. CureLauncher Introduces Personalized Clinical Trial Matching Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... 20, 2017 , ... As part of an effort coordinated by more than ... has provided input to the U.S. Senate on health care reform. , The group ... E. Schumer (D - NY) and all other Senate members. This correspondence provides legislators ...
(Date:6/19/2017)... , ... June 19, 2017 , ... ... brand new operating rooms this month. These additions will expand the capabilities of ... state-of-the-art facilities. One operating room will be solely dedicated to pediatric operations, while ...
(Date:6/19/2017)... ... June 19, 2017 , ... Haute ... to its exclusive network of beauty and wellness experts. , With two decades ... Beauty readers on hair care and restoration. , Heading the ...
(Date:6/19/2017)... ... June 19, 2017 , ... ... the general availability of several new and improved features to their Workplace ... Way iGuide data in support of national campaigns. The latest release also ...
(Date:6/19/2017)... ... 2017 , ... Bioclinica® eHealth Solutions, which provides an agile ... the launch of Clean Patient Optics ™, a first-of-its kind, fully-validated clinical ... and clinical trial timelines. The innovative product provides uninterrupted visibility into patient data ...
Breaking Medicine News(10 mins):
(Date:5/26/2017)... BARBARA, Calif. , May 25, 2017  In ... United States , Direct Relief is working with ... overdose-reversing Naloxone available at no cost to community health ... other nonprofit providers nationwide. "Pfizer has ... access to medicines and ensuring patient safety through educational ...
(Date:5/23/2017)... May 23, 2017  Leaf Healthcare, recognized for ... devices for pressure ulcer prevention, will unveil its ... of Critical Care Nurses, National Teaching Institute and ... The Leaf Patient Monitoring System is the ... hospital environment.  The system seamlessly tracks patient movement ...
(Date:5/22/2017)... , May 22, 2017  As the ... a whole continue to make the revolutionary shift ... increasingly important for ensuring positive patient outcomes and ... stakeholders are shifting focus away from clinical trials ... effects of long-term specialty drug therapy utilization in ...
Breaking Medicine Technology: